Identify predictive markers for drug response
Most drugs and therapies developed to date do not work equally well for all patients, with significant variations in efficacy and safety among individuals. Frequently, a significant proportion of patients simply fail to respond, resulting in wasted treatment costs with no benefit to the patient. A simple test to accurately predict whether an individual will respond positively to a given therapy would greatly benefit all patients, clinicians, and reimbursement authorities alike and also provide new drug development opportunities to target non-responsive patient groups.
Selected webinars
Dr. Hurtado-Lorenzo, VP of Translational Research for the Crohn’s & Colitis Foundation presents the outcome from a major study to find prognostic markers that can determine if children with Crohn’s disease will develop serious complications such as fibrosis and/or fistulas. He also describes the identification of protein biomarkers that predict whether they are likely to respond to anti-TNF therapy.
Selected publications
Olink’s PEA technology is increasingly employed in the analysis of samples from human clinical trials, identifying circulating biomarkers that can monitor the effects of therapeutic interventions and predict which individuals are likely to respond to treatment.
A flexible platform that accelerates your research
Olink’s scalable technology provides optimized solutions for every stage of the biomarker workflow, from high-throughput discovery through validation and clinical utility.
Get help choosing. Talk to a Specialist.
Olink Explore HT
Measure 5,400+ proteins with proven specificity to gain an understanding of disease at the protein level.
Proteins
5,400+ With proven specificity
Sample
2 µL Plasma, serum & more
Olink Flex
Run individually tailored studies by combining up to 21 biomarkers from our extensive library with minimal sample volume.
Proteins
~200 Pre-validated assays
Sample
1 µL Plasma, serum & more
Olink Target 96
Target specific disease areas or key biological processes with multiplex immunoassay panels.
Proteins
1,100+ On 15 targeted panels
Sample
1 µL Plasma, serum & more
Olink Target 48
Extensively validated and carefully selected biomarkers for a comprehensive view of cytokine signaling and inflammatory processes.
Proteins
89 On 2 panels
Sample
1 µL Plasma, serum & more